MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, when one of the exploratory https://stevenr888eqb1.blogofchange.com/profile